JP2017507928A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507928A5 JP2017507928A5 JP2016550203A JP2016550203A JP2017507928A5 JP 2017507928 A5 JP2017507928 A5 JP 2017507928A5 JP 2016550203 A JP2016550203 A JP 2016550203A JP 2016550203 A JP2016550203 A JP 2016550203A JP 2017507928 A5 JP2017507928 A5 JP 2017507928A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- enzalutamide
- arn
- reference example
- adsorbent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 12
- 229960004671 enzalutamide Drugs 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000008118 PEG 6000 Substances 0.000 description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- -1 fatty acid esters Chemical class 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229940085728 xtandi Drugs 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- FSVSNKCOMJVGLM-UHFFFAOYSA-N octanoic acid;propane-1,2-diol Chemical class CC(O)CO.CCCCCCCC(O)=O FSVSNKCOMJVGLM-UHFFFAOYSA-N 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019238913A JP6934932B2 (ja) | 2014-02-05 | 2019-12-27 | アンドロゲン受容体アンタゴニストの固体医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14154047.6 | 2014-02-05 | ||
| EP14154047 | 2014-02-05 | ||
| PCT/EP2015/052311 WO2015118015A1 (en) | 2014-02-05 | 2015-02-04 | Solid pharmaceutical compositions of androgen receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238913A Division JP6934932B2 (ja) | 2014-02-05 | 2019-12-27 | アンドロゲン受容体アンタゴニストの固体医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507928A JP2017507928A (ja) | 2017-03-23 |
| JP2017507928A5 true JP2017507928A5 (cg-RX-API-DMAC7.html) | 2018-03-08 |
| JP6666254B2 JP6666254B2 (ja) | 2020-03-13 |
Family
ID=50031275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550203A Expired - Fee Related JP6666254B2 (ja) | 2014-02-05 | 2015-02-04 | アンドロゲン受容体アンタゴニストの固体医薬組成物 |
| JP2019238913A Expired - Fee Related JP6934932B2 (ja) | 2014-02-05 | 2019-12-27 | アンドロゲン受容体アンタゴニストの固体医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238913A Expired - Fee Related JP6934932B2 (ja) | 2014-02-05 | 2019-12-27 | アンドロゲン受容体アンタゴニストの固体医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160346207A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3102183A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6666254B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20160113294A (cg-RX-API-DMAC7.html) |
| CN (2) | CN112402360A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015215000B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2940984A1 (cg-RX-API-DMAC7.html) |
| EA (2) | EA037895B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX386859B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015118015A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3305285T (lt) | 2012-09-26 | 2020-12-10 | Aragon Pharmaceuticals, Inc. | Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį |
| PL3226843T3 (pl) * | 2014-12-05 | 2021-12-13 | Aragon Pharmaceuticals, Inc. | Kompozycje przeciwnowotworowe |
| CN114886852A (zh) | 2014-12-05 | 2022-08-12 | 阿拉贡药品公司 | 抗癌组合物 |
| CA2969661C (en) * | 2014-12-05 | 2023-04-25 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| MX2018014846A (es) * | 2016-06-03 | 2019-03-14 | Aragon Pharmaceuticals Inc | Composiciones antineoplasicas. |
| WO2017221144A1 (en) * | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
| EP3500310A1 (en) | 2016-08-20 | 2019-06-26 | FTF Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
| KR102684756B1 (ko) * | 2017-04-28 | 2024-07-15 | 아스텔라스세이야쿠 가부시키가이샤 | 엔잘루타미드를 함유하는 경구 투여용 의약 조성물 |
| WO2019008426A1 (en) * | 2017-07-04 | 2019-01-10 | Bdr Pharmaceuticals International Private Limited | NOVEL ENZALUTAMIDE ORAL GALENIC FORM COMPOSITION AND METHOD OF MANUFACTURING THE SAME |
| WO2019016747A1 (en) * | 2017-07-20 | 2019-01-24 | Dr. Reddy's Laboratories Limited | AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION |
| RU2020109948A (ru) * | 2017-08-08 | 2021-09-10 | Др. Редди'З Лабораториз Лимитед | Экструдированные композиции энзалутамида |
| CZ2018234A3 (cs) | 2018-05-21 | 2019-12-04 | Zentiva Ks | Zvýšení rozpustnosti a biodostupnosti enzalutamidu |
| CN108815129A (zh) * | 2018-07-12 | 2018-11-16 | 天津双硕医药科技有限公司 | 一种恩杂鲁胺纳米晶体口服固体药物组合物 |
| ES2943492T3 (es) | 2018-11-30 | 2023-06-13 | Chemocentryx Inc | Formulación de cápsulas |
| JP2022533463A (ja) * | 2019-05-23 | 2022-07-22 | ヘルム・アクチエンゲゼルシャフト | エンザルタミドを含むナノ粒子 |
| EP4037659B1 (en) | 2019-10-03 | 2025-11-19 | Synthon BV | Pharmaceutical composition comprising enzalutamide |
| EP3811932A1 (en) | 2019-10-22 | 2021-04-28 | Zentiva K.S. | Dosage form of apalutamide |
| US20240207239A1 (en) * | 2021-02-06 | 2024-06-27 | Sunshine Lake Pharma Co., Ltd. | Composition and preparation method therefor |
| WO2024127361A1 (en) | 2022-12-16 | 2024-06-20 | Ferring B.V. | Enzalutamide nanocrystals, methods and compositions |
| WO2025052925A1 (ja) * | 2023-09-08 | 2025-03-13 | 沢井製薬株式会社 | エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法 |
| WO2025125565A1 (en) | 2023-12-13 | 2025-06-19 | Krka, D.D., Novo Mesto | Tablet comprising enzalutamide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2448825C (en) * | 2001-06-22 | 2009-08-11 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drug |
| CN102755318B (zh) * | 2006-03-29 | 2014-09-10 | 加利福尼亚大学董事会 | 二芳基硫代乙内酰脲化合物 |
| US9108944B2 (en) * | 2010-02-16 | 2015-08-18 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| EP2877599B1 (en) * | 2012-07-27 | 2019-10-23 | Aragon Pharmaceuticals, Inc. | Methods and compositions for determining resistance to androgen receptor therapy |
| DK3725778T3 (da) * | 2012-09-11 | 2021-09-20 | Medivation Prostate Therapeutics Llc | Formuleringer af enzalutamid |
-
2015
- 2015-02-04 AU AU2015215000A patent/AU2015215000B2/en not_active Ceased
- 2015-02-04 JP JP2016550203A patent/JP6666254B2/ja not_active Expired - Fee Related
- 2015-02-04 KR KR1020167023987A patent/KR20160113294A/ko not_active Ceased
- 2015-02-04 CA CA2940984A patent/CA2940984A1/en not_active Abandoned
- 2015-02-04 MX MX2016010216A patent/MX386859B/es unknown
- 2015-02-04 WO PCT/EP2015/052311 patent/WO2015118015A1/en not_active Ceased
- 2015-02-04 EP EP15702494.4A patent/EP3102183A1/en not_active Withdrawn
- 2015-02-04 CN CN202011306482.5A patent/CN112402360A/zh active Pending
- 2015-02-04 KR KR1020207003272A patent/KR20200015830A/ko not_active Ceased
- 2015-02-04 CN CN201580015541.4A patent/CN106102716A/zh active Pending
- 2015-02-04 EA EA201691568A patent/EA037895B1/ru unknown
- 2015-02-04 EA EA201891397A patent/EA201891397A1/ru unknown
- 2015-02-04 US US15/114,890 patent/US20160346207A1/en not_active Abandoned
-
2019
- 2019-12-27 JP JP2019238913A patent/JP6934932B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-24 US US16/751,521 patent/US20200163882A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507928A5 (cg-RX-API-DMAC7.html) | ||
| JP2014139229A5 (cg-RX-API-DMAC7.html) | ||
| Guido et al. | Pendant bioconstructions cemented by microbial carbonate in submerged marine caves (Holocene, SE Sicily) | |
| NZ596657A (en) | Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof | |
| JP2018504445A5 (cg-RX-API-DMAC7.html) | ||
| JP2018039833A5 (cg-RX-API-DMAC7.html) | ||
| MY158675A (en) | Fat-reduced soybean protein material and soybean emulsion composition, and processes for production thereof | |
| PE20190662A1 (es) | Composiciones farmaceuticas que contienen derivados de piridona policiclicos sustituidos y profarmaco de los mismos | |
| JP2016065086A5 (cg-RX-API-DMAC7.html) | ||
| UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
| MX2015011074A (es) | Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma. | |
| EP4245369A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| NZ612159A (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| JP2014111672A5 (cg-RX-API-DMAC7.html) | ||
| JP2008533007A5 (cg-RX-API-DMAC7.html) | ||
| JP2015113331A5 (cg-RX-API-DMAC7.html) | ||
| MD4673B1 (ro) | Letermovir amorf şi forme preparative farmaceutice solide ale acestuia pentru administrare orală | |
| RU2013141534A (ru) | Составы l-ментола, состоящие из множества частиц, и связанные с ними способы | |
| JP2012001634A5 (cg-RX-API-DMAC7.html) | ||
| JP2016526574A5 (cg-RX-API-DMAC7.html) | ||
| JP2018521056A5 (cg-RX-API-DMAC7.html) | ||
| JP2011225600A5 (cg-RX-API-DMAC7.html) | ||
| PE20212367A1 (es) | Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas | |
| WO2013104995A3 (en) | Compositions and methods for treating viral infections | |
| RU2013113201A (ru) | Иммуногенная композиция |